Secondary analysis of the Prostate Cancer Prevention Trial linked to Medicare claims (14,239 men, median 20 years): none of 22 conditions attributed to post-finasteride syndrome was significantly associated with finasteride vs placebo.
Secondary analysisn = 14,239
Till et al. No Evidence of Post-finasteride Syndrome in 267,983 Person-years Follow-up in the Prostate Cancer Prevention Trial